DHQP Updates

Denise M. Cardo M.D.
Director, Division of Healthcare Quality Promotion
Healthcare Infection Control Practices Advisory Committee (HICPAC)

November 15, 2018
Preventing Infections and Combating Antibiotic Resistance in Healthcare and Community Settings

Centers for Disease Control and Prevention Strategy

Detect & Contain

Improve Use

Prevent Infections

Patient Safety

Practices - Programs - Policies
HAI Prevalence Survey (2015) highlights progress made and areas where more work is needed

Patients were 16% less likely to have an HAI in 2015 than they were in 2011

---

**Most Common Infection Types**

<table>
<thead>
<tr>
<th>Infection Type</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>pneumonia</td>
<td>26%</td>
</tr>
<tr>
<td>gastrointestinal infections</td>
<td>21%</td>
</tr>
<tr>
<td>surgical site infections</td>
<td>16%</td>
</tr>
<tr>
<td>BSI unrelated to an infection at another site</td>
<td>12%</td>
</tr>
<tr>
<td>urinary tract infections</td>
<td>9%</td>
</tr>
</tbody>
</table>

---

C. difficile infections in the United States: healthcare exposures are critical to community-onset
Gradual decline in hospital-onset MRSA bacteremia, 2011-2014

NHSN’s new SIR baseline shows 6.5% decline, 2015-2016

**HHS Target:** Reduce hospital-onset MRSA bacteremia SIR by 50% by 2020 from 2015 baseline

NHSN, 2011-2018; ACH: acute care hospitals; CMS requirements began in 2013.
Community-associated (CA)
Healthcare-associated, community-onset (HACO)
Hospital onset (HO)

N = 7 Sites

Proportion of MRSA Bacteremia Events by Epiclass, 2015, NHSN

Community-onset: A large part of MRSA Bacteremia (EIP)

Distribution of MRSA BSI by Epiclass, 2016, EIP

CA, 24%
HACO, 61%
HO, 15%

Community-onset, healthcare facility-associated
Clabsi Role

N = 72,852

CLABSI Role

HO, 27.6%
CO, 58.4%
CO-HCFA, 13.9%
Percentage of invasive MRSA cases that are in PWID—6 EIP sites*

In 2017, 29% of invasive MRSA in MD and 25% in NY were associated with injection drug use.

*Does not include CO, MD, OR (similar increases from 2010-2014) or NM (no data)


URI=Upper respiratory infection

30% of outpatient antibiotics prescribed in U.S. doctor’s offices, hospital clinics and emergency departments are unnecessary

Diagnoses leading to antibiotics in doctors’ offices, hospital clinics and emergency departments — US, 2010–11

URI=Upper respiratory infection
76% of U.S. hospitals have an antibiotic stewardship program that meets CDC’s Core Elements
270.2 million antibiotic prescriptions were dispensed in U.S. outpatient pharmacies in 2016

Advances in optimizing antibiotic prescribing in outpatient settings, BMJ (November 2018): Publication summarizes the evidence on drivers of inappropriate outpatient antibiotic prescribing and potential interventions to improve outpatient antibiotic use
Collaborating with domestic and international partners to raise awareness of the threat of AR and need to improve antibiotic prescribing and use.

Promoting *Be Antibiotics Aware*, CDC’s national educational effort to keep patients safe, decrease adverse drug events, and help fight antibiotic resistance.

Highlighting AMR Challenge commitments organizations made to fight against AR.

Aligns with World Health Organization’s World Antibiotic Awareness Week and European Centre for Disease Prevention and Control’s European Antibiotic Awareness Day.
CDC educates patients, physicians, and public about the importance of sepsis prevention and early intervention.
The Containment Strategy

- Rapid detection in health care facilities
- Infection control assessments led by the health department
- Colonization screenings, when needed
- Coordination between healthcare facilities
- Continued vigilance until spread is controlled
Antibiotic Resistance Laboratory Network

Nationwide lab capacity to detect AR in healthcare, food, and community. Tracks resistance to identify outbreaks faster, stop spread, and protect people.

- CDC lab expertise and coordination
- 7 regional labs
- 1 National TB Molecular Surveillance Center
- 56 state and local labs
Containment Strategy and AR Laboratory Network enable rapid detection of and response to novel resistance

<table>
<thead>
<tr>
<th>Activity</th>
<th>2017</th>
<th>As of 8/31/2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cumulative number of isolates tested by AR Lab Network (CRE, CRPA)</td>
<td>11,557</td>
<td>12,376</td>
</tr>
<tr>
<td>Cumulative number of colonization screening swabs tested by AR Lab Network</td>
<td>2,022</td>
<td>6,581</td>
</tr>
<tr>
<td>Cumulative number of CDG-supported AR containment responses</td>
<td>152</td>
<td>107</td>
</tr>
</tbody>
</table>
THE AMR CHALLENGE
Will you fight or fuel antimicrobial resistance?

CDC along with HHS is leading a yearlong initiative to bolster global efforts across sectors and around the world to step up, partner, and each play our part in the fight against AMR.

Launched by HHS Sec. Azar at the U.N. General Assembly in Sept. 2018, more than 130 commitments have come in from governments, private industry, and civil society from around the world across the five commitment areas.

This initiative will conclude in September 2019 at the U.N. General Assembly meeting to show the global progress and commitment to continue the fight against AMR around the world.

Learn more on CDC’s website at CDC.gov/drugresistance.

Challenge Focus Areas

Across five commitment areas, commit to action and results that combat antimicrobial resistance.

Tracking and Data
Share data and improve data collection

Infection Prevention and Control
Reduce the spread of resistant germs

Antibiotic Use
Improve appropriate antibiotic use, including ensuring access

Environment and Sanitation
Decrease antibiotics and resistance in the environment

Vaccines, Diagnostics, Therapeutics
Invest in development and improved access

THE #GLOBALAMRCHALLENGE SEP. 2018-SEPT. 2019
<table>
<thead>
<tr>
<th>Event</th>
<th>Date</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>2nd World Sepsis Congress</td>
<td>September 2018</td>
<td></td>
</tr>
<tr>
<td>Interdisciplinary Sepsis Symposium</td>
<td>September 2018</td>
<td>Chicago</td>
</tr>
<tr>
<td>Sepsis Alliance: Sepsis Heroes</td>
<td>September 2018</td>
<td>New York City</td>
</tr>
<tr>
<td>Rory Staunton Foundation 5th National Forum on Sepsis</td>
<td>October 2018</td>
<td>New York City</td>
</tr>
<tr>
<td>World Health Summit</td>
<td>October 2018</td>
<td>Berlin</td>
</tr>
<tr>
<td>Global Grand Challenges Gates Foundation</td>
<td>October 2018</td>
<td>Berlin</td>
</tr>
</tbody>
</table>

Dr. Anne Schuchat presented remarks on CDC’s recent work and plans on battling sepsis in the U.S. at The Rory Staunton Foundation’s National Forum on Sepsis.